Upstream Bio, Inc. (UPB)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy
I am initiating a Buy rating on Verekitug, the lead asset of Upstream Bio, a small-cap biotech trading at an enterprise value under $200M. Verekitug's quarterly dosing and differentiated TSLPR mechanism offer competitive efficacy in severe asthma and CRSwNP, with strong phase 2 data supporting further development. UPB's key catalysts include FDA interactions, phase 3 trial initiations in 2027, and a COPD phase 2 readout, all of which could drive significant re-rating.
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $0.51 per share a year ago.
Upstream Bio, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 1 | $27 | $7.13 | -$19.87 | -73.59% |
 Point72 Asset Management LP Point72 Asset Management LP | 178,168 | $1.6M | $1.28M | -$322,484.08 | -20.11% |
 Joseph Castro Nuveen LLC | 75,536 | $894,507.46 | $542,136.98 | -$352,370.48 | -39.39% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 2 | $18 | $14.44 | -$3.56 | -19.78% |
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 31 | $279 | $223.51 | -$55.49 | -19.89% |
Upstream Bio, Inc. (UPB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Upstream Bio, Inc. ever had a stock split?
Upstream Bio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | E. Rand Sutherland CEO | NASDAQ (NGS) Exchange | 91678A107 CUSIP |
| US Country | 75 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Upstream Bio, Inc. is a clinical-stage biotechnology firm founded in 2021 with its headquarters in Waltham, Massachusetts. The company is at the forefront of developing innovative treatments for inflammatory diseases, primarily focusing on severe respiratory disorders. Its research and development efforts are centered on discovering monoclonal antibodies and other therapeutic strategies that can significantly improve the quality of life for individuals suffering from severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease (COPD).
Products and Services
- Verekitug: A pioneering monoclonal antibody developed by Upstream Bio, Inc., Verekitug targets and inhibits the thymic stromal lymphopoietin receptor. This specific targeting mechanism offers a novel approach to treating inflammatory diseases by directly intervening in the inflammatory pathways that exacerbate severe respiratory disorders.
- Severe Asthma Therapies: Upstream Bio is dedicated to developing advanced treatments for severe asthma. These therapies aim to provide relief for patients whose condition cannot be adequately managed with conventional asthma medications, focusing on reducing the frequency and severity of asthma attacks.
- Chronic Rhinosinusitis with Nasal Polyps Treatments: The company also concentrates on creating therapies for chronic rhinosinusitis with nasal polyps, a condition that leads to breathing difficulties, nasal congestion, and reduced quality of life. These treatments seek to reduce inflammation and the size of nasal polyps, improving airflow and symptoms.
- Chronic Obstructive Pulmonary Disease (COPD) Solutions: Addressing the needs of individuals suffering from COPD, Upstream Bio, Inc. is in the process of developing therapies that alleviate the symptoms, improve lung function, and enhance the overall health status of COPD patients. These solutions are aimed at treating the chronic inflammation and preventing the progression of the disease.
